Health Care Services

GUSHENGTANG

Tongsheng Tang spends 10.73 million HKD to repurchase 396,300 shares

MedTong Holdings to hold AGM on June 18 to review dividends and board election

Gu Sheng Tang repurchased 85,000 shares for HKD 2,499,700

Gusheng Tang repurchased 9,500 ordinary shares

Guosheng Tang Holding to Hold Extraordinary General Meeting to Review Share Repurchase Authorization

BOCOM Maintains Buy Rating on GusherTang

GUSHENGTANG released FY2025 9 Months Earnings on March 31 (BJT), actual revenue HKD 2.577 B, actual EPS HKD 1.1266

GUSHENGTANG released FY2025 Q3 earnings on March 31 (BJT), actual revenue HKD 958.8 M, actual EPS HKD 0.4549

GUSHENGTANG released FY2025 Annual Earnings on March 31 During-Market (BJT), Actual Revenue: HKD 3.551 B (Forecast: HKD 3.792 B), Actual EPS: HKD 1.5847 (Forecast: HKD 1.794)

GUSHENGTANG released FY2025 Q4 earnings on March 31 During-Market (BJT), actual revenue HKD 975.35 M, actual EPS HKD 0.4631

GUSHENGTANG to Release FY2025 Earnings on March 31 During-Market (BJT), Forecast Revenue HKD 3.88 B, EPS HKD 1.8123

Gusheng Tang Subsidiary Plans to Acquire Equity in Three Companies to Expand Offline Medical Institutions Network

Good Health TCM Group Launches a Collaboration Project with Nanyang Technological University in Singapore

Gusheng Tang Holding Limited repurchased 134,400 shares

Gushentang Repurchased 340,100 Shares for HKD 9,597,300

Good Health Holding Convenes Year-End Expert Gala to Unveil TCM AI Model Collaboration and Achievements

Gusheng Tang Holding Repurchased Shares

Gusheng Tang repurchased 200,000 shares for about HK$5.7193 million

Gusheng Tang Holding Limited repurchased 320,000 shares

Gusheng Tang repurchased 287,600 shares for HKD 8.5854 million

SYNERTONE

SOFTMEDX

TAILAM TECHCON

HIPINE

BIOSTAR PHARM-B

WING FUNG GROUP

PAN ASIA DATA H

G-VISION INT'L

MEDINET GROUP

Ordinary dividend (cash)

Ex Date: 2026.06.24, Cash dividend 0.69 HKD

02273

Gushengtang Holdings Limited announced board changes effective May 12, 2026, with independent non-executive director Li Tie resigning as audit committee chair to focus on other commitments. Finance scholar Chang Xin has been appointed as his replacement, expected to enhance financial oversight and governance. The company aims to strengthen investor confidence and align with international best practices. The latest analyst rating for Gushengtang stock (HK:2273) is a Sell with a price target of HK$24.50. Gushengtang operates in the healthcare sector, focusing on traditional Chinese medicine.

Tip Ranks

Gushengtang reshapes board with new audit chair as veteran director exits

In a report released yesterday, from Orient Securities maintained a Buy rating on Gushengtang Holdings Limited, with a price target of HK$40.43.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Gushengtang Holdings Limited is a Strong Buy with an average price target of HK$38.34.

DFZQ

Gushengtang Holdings Limited (2273) Receives a Buy from Orient Securities

516610

In a report released yesterday, from Huatai Securities maintained a Buy rating on Gushengtang Holdings Limited, with a price target of HK$45.68.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Gushengtang Holdings Limited is a Strong Buy with an average price target of HK$40.11.

Dacheng CSI All Share Health Care Equipment and Services ETF

Gushengtang Holdings Limited (2273) Gets a Buy from Huatai Securities

BOCOM International Holdings Company analyst maintained a Buy rating on Gushengtang Holdings Limited yesterday and set a price target of HK$34.20.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Gushengtang Holdings Limited is a Strong Buy with an average price target of HK$40.11.

BOCOM International Holdings Company Reaffirms Their Buy Rating on Gushengtang Holdings Limited (2273)

GUSHENGTANG announced its 2025 annual performance, with revenue of RMB 3.249 billion, an increase of 7.5% year-on-year; gross profit of RMB 1.012 billion, an increase of 11.3%. It recorded a net profit of RMB 353 million, a growth of 15%, with earnings per share of RMB 1.49. The final dividend is HKD 0.69, compared to HKD 0.41 in the same period last year

AASTOCKS

"GUSHENGTANG" reported a net profit of RMB 353 million for the year, an increase of 15%, with a final dividend of HKD 0.69

02677

Chinese healthcare firms are expanding overseas to serve expatriate communities, particularly in the Middle East and Southeast Asia. Distinct Healthcare Holdings plans to open a clinic in Dubai after raising HK$284.53 million from its IPO in Hong Kong. Traditional Chinese medicine companies like Sichuan Neautus are also exporting products to Southeast Asia, capitalizing on the demand from overseas Chinese communities. Gushengtang Holdings aims to open 50 clinics in the region by 2026. This trend reflects a broader movement of mainland companies utilizing Hong Kong's capital markets for international expansion.

SCMP

DISTINCT HEALTH

Chinese healthcare firms expand overseas to support growing expat community

Nanyang Technological University Singapore and Gu Sheng Tang have launched the ‘Gu Sheng Tang Traditional Chinese Medicine Education and Research Programme’ with a $1.06 million donation. This initiative aims to advance evidence-based TCM research and develop talent by bringing Chinese TCM experts to Singapore for mentorship and lectures. It also includes doctoral scholarships and support for international academic exchanges to cultivate a globally oriented TCM workforce.

Singapore Business Review

NTU, Gu Sheng Tang push TCM research with $1.06m programme

GUSHENGTANG(02273.HK)